Back to results
US 2023/0407328 A1Published application
Process for enriching adeno-associated virus
AssigneeBiomarin Pharmaceutical Inc.
InventorsJohn MAGA, Harmit VORA, Rahul SHETH, Daniel GOLD, Anant RISHI, Yanhong ZHANG, Kieu TRAN
Life of this patent
Estimating the term…
Abstract
The present invention provides process for enriching adeno-associated virus particles using anion exchange chromatography and zonal ultracentrifugation.
Claims23
A method of purifying therapeutically effective recombinant adeno-associated virus (rAAV) particles, the method comprising the steps of:
- providing a composition including therapeutically effective rAAV particles and AAV production impurities, where a first portion of the AAV production impurities comprises impurities having a net charge different from the AAV particles and a second portion of the AAV production impurities comprises impurities having a density different from the AAV particles;
- removing the first portion from the composition by anion-exchange chromatography;
- and
- removing the second portion from the composition by zonal ultracentrifugation;
- wherein, after anion-exchange chromatography and zonal ultracentrifugation, the composition is substantially devoid of AAV production impurities.
2 more elements
6-16. (canceled)
A method of purifying therapeutically effective recombinant adeno-associated virus (rAAV) particles, the method comprising the steps of:
- providing a composition including therapeutically effective rAAV particles and therapeutically ineffective rAAV particles;
- removing at least some of the therapeutically ineffective rAAV particles from the composition by anion-exchange chromatography;
- and
- processing the composition by zonal ultracentrifugation;
- wherein, after anion-exchange chromatography and zonal ultracentrifugation, the composition is substantially devoid of therapeutically ineffective rAAV particles.
2 more elements
(canceled)
29-31. (canceled)
Dependencies are inferred from the claim text.